上海醫藥(02607.HK):注射用頭孢唑肟鈉通過仿製藥一致性評價
格隆匯3月17日丨上海醫藥(02607.HK)公告,近日,公司控股子公司上海上藥新亞藥業有限公司收到國家藥品監督管理局(以下簡稱“國家藥監局”)頒發的關於注射用頭孢唑肟鈉的《藥品補充申請批準通知書》(通知書編號:2025B00884),該藥品通過仿製藥一致性評價。
注射用頭孢唑肟鈉主要適用於敏感菌所致的下呼吸道感染、尿路感染、腹腔感染、盆腔感染、敗血癥、皮膚軟組織感染、骨和關節感染、肺炎鏈球菌或流感嗜血桿菌所致腦膜炎和單純性淋病,由日本藤澤藥業工業株式會社(現爲安斯泰來製藥株式會社)研發,1983年在美國上市。2023年9月,上藥新亞就該藥品仿製藥一致性評價向國家藥監局提出申請並獲受理。
截至本公告日,公司針對該藥品的一致性評價已投入研發費用約人民幣500萬元。截至本公告日,中國境內該藥品的主要生產廠家包括西南藥業股份有限公司、國藥集團致君(深圳)製藥有限公司、成都倍特藥業股份有限公司等。IQVIA數據庫顯示,2024年該藥品注射劑醫院採購金額爲人民幣360,877萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.